IGF-1R Antibodies With Extended Half-Lives for Thyroid Eye Disease Treatment
Summary
USPTO granted US Patent US12600788B2 to Viridian Therapeutics, Inc. covering antibodies and compositions targeting Insulin-Like Growth Factor-1 Receptor (IGF-1R) with extended half-lives for treating thyroid eye disease. The patent contains 18 claims and names six inventors including Vahe Bedian, Peter Harwin, and Jonathan Violin.
What changed
USPTO issued US Patent US12600788B2 to Viridian Therapeutics, Inc. for compositions and methods relating to IGF-1R-targeting antibodies with extended half-lives. The patent specifically covers uses for treating or reducing severity of thyroid eye disease in subjects by inhibiting IGF-1R activity.
For pharmaceutical and biotech companies developing IGF-1R-targeted therapies for thyroid eye disease, this patent establishes proprietary intellectual property held by Viridian. Competitors pursuing similar IGF-1R antibody approaches for TED will need to consider freedom-to-operate implications or potential licensing arrangements.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compositions and methods for treatment of thyroid eye disease
Grant US12600788B2 Kind: B2 Apr 14, 2026
Assignee
Viridian Therapeutics, Inc.
Inventors
Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
Abstract
Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) with extended half-lives and uses thereof are provided herein. Antibodies and compositions described herein can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, by inhibiting the activity of IGF-1R with such antibodies and compositions.
CPC Classifications
C07K 16/2863 A61P 27/02
Filing Date
2025-06-18
Application No.
19242725
Claims
18
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.